| Year of Transplant | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | ||
| Functioning Graft at Discharge | 49 | 61 | 88 | 89 | 103 | 130 | 155 | 148 | 166 | 168 | |
| With Immunosuppression Info | 49 | 61 | 88 | 89 | 103 | 127 | 152 | 148 | 166 | 167 | |
| Corticosteroids | Any in Category | 93.9% | 96.7% | 79.5% | 66.3% | 67.0% | 74.8% | 71.1% | 73.6% | 77.1% | 78.4% |
| Steroids | 93.9% | 96.7% | 79.5% | 66.3% | 67.0% | 74.8% | 71.1% | 73.6% | 77.1% | 78.4% | |
| Cyclosporine | Any in Category | 4.1% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% |
| Neoral | 4.1% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | |
| Tacrolimus | Any in Category | 95.9% | 95.1% | 97.7% | 95.5% | 93.2% | 97.6% | 96.7% | 98.0% | 97.0% | 98.8% |
| Tacrolimus | 95.9% | 95.1% | 97.7% | 95.5% | 93.2% | 97.6% | 96.7% | 98.0% | 97.0% | 98.8% | |
| Antimetabolites | Any in Category | 24.5% | 21.3% | 10.2% | 12.4% | 8.7% | 8.7% | 12.5% | 19.6% | 22.9% | 24.6% |
| Mycophenolate Mofetil | 18.4% | 14.8% | 3.4% | 11.2% | 8.7% | 8.7% | 12.5% | 18.9% | 21.1% | 24.0% | |
| Mycophenolate Sodium | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Azathioprine | 6.1% | 6.6% | 6.8% | 1.1% | 0.0% | 0.0% | 0.0% | 0.7% | 1.8% | 0.6% | |
| mTOR Inhibitors | Any in Category | 2.0% | 39.3% | 21.6% | 20.2% | 5.8% | 11.8% | 12.5% | 10.1% | 9.0% | 9.6% |
| Sirolimus | 2.0% | 39.3% | 21.6% | 20.2% | 5.8% | 11.8% | 12.5% | 10.1% | 9.0% | 9.6% | |
| Everolimus | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |